Nuclear factor-κB in thyroid carcinogenesis and progression: A novel therapeutic target for advanced thyroid cancer

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 5, 2007, Pages 843-851

  Namba, Hiroyuki ^a   Saenko, Vladimir ^a   Yamashita, Shunichi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Apoptosis; Molecular target therapy; NF B; Thyroid cancer

Indexed keywords

BENZAMIDE DERIVATIVE; CYCLOHEXANONE DERIVATIVE; DEHYDROXYMETHYLEPOXYQUINOMICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SERINE THREONINE KINASE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL; APOPTOSIS; CARCINOMA; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; THYROID TUMOR; TRANSACTIVATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; BENZAMIDES; CARCINOMA; CYCLOHEXANONES; ENZYME ACTIVATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRANS-ACTIVATION (GENETICS);

EID: 35348816753     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302007000500023     Document Type: Review

References (83)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
2. Wyllie AH, Morris RG, Smith AL, Dunlop D. Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 1984;142:67-77.
3. Zhivotovsky B. More than one road to kill tumor cells - why are they not always successful? Cell Cycle 2003;2(1):31-3.
4. Namba H, Hara T, Tukazaki T, Migita K, Ishikawa N, Ito K, et al. Radiation-induced G1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells. Cancer Res 1995;55:2075-80.
5. Mitsiades CS, Poulaki V, Mitsiades N. The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer. J Endocrinol 2003;178:205-16.
6. Basolo F, Pollina L, Fontanini G, Fiore L, Pacini F, Baldanzi A. Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p53 protein expression. Br J Cancer 1997;75:537-41.
7. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Chrousos GP, Koutras DA. Fas ligand expression in thyroid follicular cells from patients with thionamide-treated Graves' disease. Thyroid 2000;10:527-32.
8. Arscott PL, Stokes T, Myc A, Giordano TJ, Thompson NW, Baker JR, Jr. Fas (CD95) expression is up-regulated on papillary thyroid carcinoma. J Clin Endocrinol Metab 1999;84:4246-52.
9. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-κB transcription factors. Oncogene 1999;18:6910-24.
10. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
11. Zandi E, Karin M. Bridging the gap: composition, regulation, and physiological function of the IκB kinase complex. Mol Cell Biol 1999;19:4547-51.
12. Karin M, Delhase M. The IκB kinase (IKK) and NF-κB: key elements of proinflammatory signalling. Semin Immunol 2000;12:85-98.
13. Baldwin AS, Jr. Series introduction: the transcription factor NF-κB and human disease. J Clin invest 2001;107:3-6.
14. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-3.
15. Wu MX, Ao Z, Prasad KV, Wu R, Schlossman SF. IEX-1L, an apoptosis inhibitor involved in NF-κB-mediated cell survival. Science 1998;281:998-1001.
16. Karin M, Lin A. NF-κB at the crossroads of life and death. Nat Immunol 2002;3:221-7.
17. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, et al. Activation by IKK? of a second, evolutionary conserved, NF-κB signaling pathway. Science 2001;293:1495-9.
18. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-52.
19. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A, et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000;288:870-4.
20. De Smaele E, Zazzeroni F, Papa S, Nguyen DU, Jin R, Jones J, et al. Induction of gadd45β by NF-κB downregulates pro-apoptotic JNK signalling. Nature 2001;414:308-13.
21. Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M, et al. Inhibition of JNK activation through NF-κB target genes. Nature 2001;414:313-7.
22. Javelaud D, Besancon F. NF-κB activation results in rapid inactivation of JNK in TNFα-treated Ewing sarcoma cells: a mechanism for the anti-apoptotic effect of NF-κB. Oncogene 2001;20:4365-72.
23. Zhang Y, Chen F. Reactive oxygen species (ROS), troublemakers between nuclear factor-κB (NF-κB) and c-Jun NH(2)-terminal kinase (JNK). Cancer Res 2004;64:1902-5.
24. Papa S, Zazzeroni F, Pham CG, Bubici C, Franzoso G. Linking JNK signaling to NF-κB: a key to survival. J Cell Sci 2004;117:5197-208.
25. Kaur S, Wang F, Venkatraman M, Arsura M. X-linked inhibitor of apoptosis (XIAP) inhibits c-Jun N-terminal kinase 1 (JNK1) activation by transforming growth factor beta 1 (TGF-β1) through ubiquitin-mediated proteosomal degradation of the TGF-beta1-activated kinase 1 (TAK1). J Biol Chem 2005;280:38599-608.
26. Sakon S, Xue X, Takekawa M, Sasazuki T, Okazaki T, Kojima Y, et al. NF-κB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J 2003;22:3898-909.
27. Luo JL, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 2005;115:2625-32.
28. Shklyaev SS, Namba H, Sautin Y, Mitsutake N, Nagayama Y, Ishikawa N, et al. Involvement of wild-type p53 in radiation-induced c-Jun N-terminal kinase activation in human thyroid cells. Anticancer Res 2001;21:2569-75.
29. Shklyaev SS, Namba H, Mitsutake N, Alipov G, Nagayama Y, Maeda S, et al. Transient activation of c-Jun NH2-terminal kinase by growth factors influences survival but not apoptosis of human thyrocytes. Thyroid 2001;11:629-36.
30. Sautin Y, Takamura N, Shklyaev S, Nagayama Y, Ohtsuru A, Namba H, et al. Ceramide-induced apoptosis of human thyroid cancer cells resistant to apoptosis by irradiation. Thyroid 2000;10:733-40.
31. Mitsutake N, Namba H, Shklyaev SS, Tsukazaki T, Ohtsuru A, Ohba M, et al. PKC delta mediates ionizing radiation-induced activation of c-Jun NH(2)-terminal kinase through MKK7 in human thyroid cells. Oncogene 2001;20:989-96.
32. Gilmore TD. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene 1999;18:6925-37.
33. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999;18:6938-47.
34. Morin CI, Huot J. Recent advances in stress signaling in cancer. Cancer Res 2004;64:1893-8.
35. Courtois G, Gilmore TD. Mutations in the NF-κB signaling pathway: implications for human disease. Oncogene 2006;25:6831-43.
36. Kucharczak J, Simmons MJ, Fan Y, Gelinas C. To be, or not to be: NF-κB is the answer - role of Rel/NF-κB in the regulation of apoptosis. Oncogene 2003;22:8961-82.
37. Orlowski RZ, Baldwin AS, Jr. NF-κB as a therapeutic target in cancer. Trends Mol Med 2002;8:385-9.
38. Romieu-Mourez R, Kim DW, Shin SM, Demicco EG, Landesman-Bollag E, Seldin DC, et al. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol 2003;23:5738-54.
39. Podolsky DK. Inflammatory bowel disease (1). N Engl J Med 1991;325:928-37.
40. Wang CY, Cusack JC, Jr., Liu R, Baldwin AS, Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nature Med 1999;5:412-7.
41. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997;100:2961-9.
42. Duffey DC, Chen Z, Dong G, Ondrey FG, Wolf JS, Brown K, et al. Expression of a dominant-negative mutant inhibitor-κBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999;59:3468-74.
43. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001;20:4188-97.
44. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell 2004;6:297-305.
45. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
46. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-6.
47. Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K, et al. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFκB p65 protein expression. Oncogene 1997;15:1987-94.
48. Starenki D, Namba H, Saenko V, Ohtsuru A, Yamashita S Inhibition of nuclear factor-κB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2004;89:410-8.
49. Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, Monaco M, et al. Oncogenic and anti-apoptotic activity of NF-κB in human thyroid carcinomas. J Biol Chem 2004;279:54610-9.
50. Mitsiades CS, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Charalambous E, et al. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab 2006;91:3662-6.
51. Fusco A, Grieco M, Santoro M, Berlingieri MT, Pilotti S, Pierotti MA, et al. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 1987;328:170-2.
52. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-7.
53. Namba H, Gutman RA, Matsuo K, Alvarez A, Fagin JA. H-ras protooncogene mutations in human thyroid neoplasms. J Clin Endocrinol Metab 1990;71:223-9.
54. Tuyt LM, Dokter WH, Birkenkamp K, Koopmans SB, Lummen C, Kruijer W, et al. Extracellular-regulated kinase 1/2, Jun N-terminal kinase, and c-Jun are involved in NF-κB-dependent IL-6 expression in human monocytes. J Immunol 1999;162:4893-902.
55. Bochner BS, Undem BJ, Lichtenstein LM. Immunological aspects of allergic asthma. Annu Rev Immunol 1994;12:295-335.
56. V600E promotes invasiveness of thyroid cancer cells through nuclear factor κB activation. Endocrinology 2006;147:5699-707.
57. Ludwig L, Kessler H, Wagner M, Hoang-Vu C, Dralle H, Adler G, et al. Nuclear factor-κB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res 2001;61:4526-35.
58. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16:64-7.
59. Vasko V, Saji M, Hardy E, Kruhlak M, Larin A, Savchenko V, et al. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer. J Med Genet 2004;41:161-70.
60. Kim D, Chung J. Akt: versatile mediator of cell survival and beyond. J Biochem Mol Biol 2002;35:106-15.
61. Jung HS, Kim DW, Jo YS, Chung HK, Song JH, Park JS, et al. Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases. Mol Endocrinol 2005;19:2748-59.
62. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 1996;274:787-9.
63. Vasudevan S, Garneau N, Tu Khounh D, Peltz SW. p38 mitogen-activated protein kinase/Hog1p regulates translation of the AU-rich-element-bearing MFA2 transcript. Mol Cell Biol 2005;25:9753-63.
64. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, et al. PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000;289:1357-60.
65. Kato Y, Ying H, Zhao L, Furuya F, Araki O, Willingham MC, et al. PPARγ insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-κB signaling pathway. Oncogene 2006;25:2736-47.
66. Bravo SB, Pampin S, Cameselle-Teijeiro J, Carneiro C, Dominguez F, Barreiro F, et al. TGF-β-induced apoptosis in human thyrocytes is mediated by p27kip1 reduction and is overridden in neoplastic thyrocytes by NF-κB activation. Oncogene 2003;22:7819-30.
67. Pang XP, Ross NS, Park M, Juillard GJ, Stanley TM, Hershman JM. Tumor necrosis factor-α activates nuclear factor κB and induces manganous superoxide dismutase and phosphodiesterase mRNA in human papillary thyroid carcinoma cells. J Biol Chem 1992;267:12826-30.
68. Jiang Y, Cui L, Yie TA, Rom WN, Cheng H, Tchou-Wong KM. Inhibition of anchorage-independent growth and lung metastasis of A549 lung carcinoma cells by IκBβ. Oncogene 2001;20:2254-63.
69. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001;107:241-6.
70. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
71. Guo J, Verma UN, Gaynor RB, Frenkel EP, Becerra CR. Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-κB p65 subunit. Clin Cancer Res 2004;10:3333-41.
72. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-42.
73. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 1998;396:77-80.
74. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
75. Holmes-McNary M, Baldwin AS, Jr. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IκB kinase. Cancer Res 2000;60:3477-83.
76. Monks NR, Biswas DK, Pardee AB. Blocking anti-apoptosis as a strategy for cancer chemotherapy: NF-κB as a target. J Cell Biochem 2004;92:646-50.
77. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94:3315-24.
78. Rousselot P, Larghero J, Arnulf B, Poupon J, Royer B, Tibi A, et al. A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia 2004;18:1518-21.
79. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 1996;15:6269-79.
80. Chen S, Fribley A, Wang CY. Potentiation of tumor necrosis factor-mediated apoptosis of oral squamous cell carcinoma cells by adenovirus-mediated gene transfer of NF-κB inhibitor. J Dent Res 2002;81:98-102.
81. Erkel G, Anke T, Sterner O. Inhibition of NF-κB activation by panepoxydone. Biochem Biophys Res Commun 1996;226:214-21.
82. Matsumoto N, Ariga A, To-e S, Nakamura H, Agata N, Hirano S, et al. Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett 2000;10:865-9.
83. Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa K, et al. Induction of thyroid cancer cell apoptosis by a novel nuclear factor κB inhibitor, dehydroxymethylepoxyquinomicin. Clin Cancer Res 2004;10:6821-9.